We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus
Read MoreHide Full Article
Key Takeaways
Moderna will receive up to $50M from CEPI to develop a Bundibugyo ebolavirus vaccine.
The funding supports early development and manufacturing to speed potential phase II/III studies.
No approved Bundibugyo ebolavirus vaccines exist, and the outbreak remains a public health emergency.
Moderna (MRNA - Free Report) announced a new collaboration with the Coalition for Epidemic Preparedness Innovations (“CEPI”) to accelerate the development of a potential vaccine targeting Bundibugyo ebolavirus (“BDBV”). This virus strain is responsible for the ongoing Ebola outbreak in the Democratic Republic of the Congo and neighboring Uganda.
Per the partnership terms, CEPI will provide up to $50 million to support preclinical and early-stage development of Moderna’s experimental BDBV vaccine. This funding will also support manufacturing activities in parallel, which would allow the program to “rapidly” advance to phase II/III studies, if the early-stage data are supportive.
The collaboration addresses a significant unmet need, as there are currently no approved vaccines for Bundibugyo ebolavirus and no BDBV vaccine candidates in clinical development. The current epidemic has already caused more than 900 suspected cases and over 220 suspected deaths. Both the World Health Organization and Africa CDC have declared the outbreak a public health emergency.
CEPI is also supporting two additional BDBV vaccine programs. It has committed up to $3.2 million to a candidate being developed by the International AIDS Vaccine Initiative and up to $8.6 million to a vaccine candidate from the University of Oxford, which will be manufactured by Serum Institute of India.
MRNA’s Stock Performance
Year to date, shares of Moderna have surged 56% compared with the industry’s nil growth.
Image Source: Zacks Investment Research
More on MRNA-CEPI Collaboration
The new BDBV vaccine program collaboration expands the existing strategic partnership between Moderna and CEPI that was formed in 2023. This partnership was formed to leverage the company’s mRNA platform to accelerate the development of vaccines against emerging epidemic and pandemic threats. The collaboration was designed to support CEPI's "100 Days Mission," which aims to develop safe, effective and accessible vaccines within 100 days of identifying a new pandemic threat.
The partnership expanded further in the last year when CEPI committed up to $54.3 million to support a pivotal phase III study of Moderna's investigational mRNA-based H5 pandemic influenza vaccine candidate. The funding is intended to help advance the vaccine toward licensure and strengthen global preparedness against future influenza pandemics. As part of the agreement, Moderna also committed to reserving 20% of its H5 vaccine manufacturing capacity for affordable supply to low and middle-income countries in the event of a pandemic.
Over the past 30 days, estimates for Immunocore’s 2026 bottom line have improved from a loss per share of 88 cents to earnings of 6 cents. Over the same period, estimates for 2027 EPS have risen from 24 cents to 87 cents. IMCR’s shares have lost 16% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters but missed the mark on one occasion, delivering an average surprise of 46.66%.
Over the past 30 days, estimates for Indivior Pharmaceuticals’ 2026 EPS have increased from $3.00 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.69 from $3.33. INDV’s shares are down 3% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 65.44%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus
Key Takeaways
Moderna (MRNA - Free Report) announced a new collaboration with the Coalition for Epidemic Preparedness Innovations (“CEPI”) to accelerate the development of a potential vaccine targeting Bundibugyo ebolavirus (“BDBV”). This virus strain is responsible for the ongoing Ebola outbreak in the Democratic Republic of the Congo and neighboring Uganda.
Per the partnership terms, CEPI will provide up to $50 million to support preclinical and early-stage development of Moderna’s experimental BDBV vaccine. This funding will also support manufacturing activities in parallel, which would allow the program to “rapidly” advance to phase II/III studies, if the early-stage data are supportive.
The collaboration addresses a significant unmet need, as there are currently no approved vaccines for Bundibugyo ebolavirus and no BDBV vaccine candidates in clinical development. The current epidemic has already caused more than 900 suspected cases and over 220 suspected deaths. Both the World Health Organization and Africa CDC have declared the outbreak a public health emergency.
CEPI is also supporting two additional BDBV vaccine programs. It has committed up to $3.2 million to a candidate being developed by the International AIDS Vaccine Initiative and up to $8.6 million to a vaccine candidate from the University of Oxford, which will be manufactured by Serum Institute of India.
MRNA’s Stock Performance
Year to date, shares of Moderna have surged 56% compared with the industry’s nil growth.
Image Source: Zacks Investment Research
More on MRNA-CEPI Collaboration
The new BDBV vaccine program collaboration expands the existing strategic partnership between Moderna and CEPI that was formed in 2023. This partnership was formed to leverage the company’s mRNA platform to accelerate the development of vaccines against emerging epidemic and pandemic threats. The collaboration was designed to support CEPI's "100 Days Mission," which aims to develop safe, effective and accessible vaccines within 100 days of identifying a new pandemic threat.
The partnership expanded further in the last year when CEPI committed up to $54.3 million to support a pivotal phase III study of Moderna's investigational mRNA-based H5 pandemic influenza vaccine candidate. The funding is intended to help advance the vaccine toward licensure and strengthen global preparedness against future influenza pandemics. As part of the agreement, Moderna also committed to reserving 20% of its H5 vaccine manufacturing capacity for affordable supply to low and middle-income countries in the event of a pandemic.
MRNA’s Zacks Rank
Moderna currently carries a Zacks Rank #3 (Hold).
Moderna, Inc. Price
Moderna, Inc. price | Moderna, Inc. Quote
Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are Immunocore (IMCR - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, estimates for Immunocore’s 2026 bottom line have improved from a loss per share of 88 cents to earnings of 6 cents. Over the same period, estimates for 2027 EPS have risen from 24 cents to 87 cents. IMCR’s shares have lost 16% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters but missed the mark on one occasion, delivering an average surprise of 46.66%.
Over the past 30 days, estimates for Indivior Pharmaceuticals’ 2026 EPS have increased from $3.00 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.69 from $3.33. INDV’s shares are down 3% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 65.44%.